Protocol to Design, Clone, and Validate sgRNAs for In Vivo Reverse Genetic Studies

AAV-CRISPR/Cas9 permits gene mutagenesis in the adult CNS. Current methods determining in vivo on-target mutagenesis have been limited by the ability to isolate virally transduced cells. This protocol optimizes a workflow for the design, cloning, and validation of sgRNAs delivered by AAVs in vivo that can be applied to any target gene in the CNS of rat or mouse model systems and can be adapted to Cre or Flp driver lines using AAV-FLEX-SaCas9-sgRNA or AAV-FLEXfrt-SaCas9-sgRNA, respectively.

HIGHLIGHTS
CRISPR/SaCas9
sgRNA design and cloning
Cre- and Flp-dependent viral gene mutagenesis
Validation of sgRNA by targeted deep sequencing
Protocol to Design, Clone, and Validate sgRNAs for In Vivo Reverse Genetic Studies

Avery C. Hunker1,2,3 and Larry S. Zweifel1,2,4,*

1Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA 98195, USA
2Department of Pharmacology, University of Washington, Seattle, WA 98195, USA
3Technical Contact
4Lead Contact
*Correspondence: larryz@uw.edu
https://doi.org/10.1016/j.xpro.2020.100070

SUMMARY

AAV-CRISPR/Cas9 permits gene mutagenesis in the adult CNS. Current methods determining in vivo on-target mutagenesis have been limited by the ability to isolate virally transduced cells. This protocol optimizes a workflow for the design, cloning, and validation of sgRNAs delivered by AAVs in vivo that can be applied to any target gene in the CNS of rat or mouse model systems and can be adapted to Cre or Flp driver lines using AAV-FLEX-SaCas9-sgRNA or AAV-FLEXfrt-SaCas9-sgRNA, respectively.

For complete details on the use and execution of this protocol, please refer to Hunker et al. (2020).

BEFORE YOU BEGIN

△ CRITICAL: This protocol consists of two distinct sections. The first section “Insertion of sgRNAs into Vector” outlines the design and cloning of sgRNAs into AAV-FLEX-SaCas9-sgRNA or AAV-FLEXfrt-SaCas9-sgRNA. The second section “Validation of sgRNA” outlines the process for obtaining deep sequencing reads with SaCas9-mediated mutations. There will be 6–8 weeks between completion of the first section and the ability to start of the second section. Please read the entire protocol carefully before beginning.

Selection and Design of sgRNAs for Insertion into AAV1-FLEX-SaCas9-sgRNA or AAV1-FLEXfrt-SaCas9-sgRNA

⊙ Timing: 1 h

1. Obtain genomic sequence from the UCSC genome browser (Waterston et al., 2002) by searching the gene name in the designated assembly, e.g., mouse or rat.
2. Import genomic sequence to DNA annotation software and label all coding exons (Figure 1A).

Note: The software Snapgene is excellent for displaying and annotating genomic information (Insightful Science; available at snapgene.com).

3. Align all known isoforms of the gene to the reference genomic sequence.
Note: Isoforms for mouse genes can be found at the Mouse Genomics Informatics (MGI) website (Bult et al., 2019; Smith et al., 2019).

4. Choose the most 5' exon that is common to all isoforms.

5. Input this sequence into the CRISPOR website (http://crispor.tefor.net/) (Concordet and Haeussler, 2018; Haeussler et al., 2016) and choose the appropriate genome (e.g., mouse or rat) and PAM (21 bp-NN(G/A)(G/A)T – Cas9 S. Aureus).

6. Choose a sgRNA that has both high specificity (fewest predicted off-target sites in exons) and high chance of a frameshift mutation.

Note: It is recommended that there are two or less predicted off-targets in exons.

7. Order the forward and reverse oligos such that the forward oligo (the one on the same strand as the PAM sequence) has “CACCG” on the 5’ end, and the reverse oligo has “AAAC” on the 5’ end, and “C” on the 3’ end (Figure 1B). Sequences with overhangs added can be directly copied from the CRISPOR website using the “U6 expression from an Addgene plasmid” and selecting pX601-AAV-CMV::NLS-SaCas9-NLS-3XHA-bGHpA;U6::BsaI-sgRNA (Zhang lab) (Ran et al., 2015).

Note: Failure to add the correct overhangs will hinder proper cloning into the vector.

Design PCR Primers for Amplification of Targeted Region following FACS of Virally Transduced Nuclei

© Timing: 30 min

8. Design forward and reverse primers for PCR 1 that span the target region with the predicted SaCas9 cut site (located in the sgRNA) in the center and will result in a ~400–600 bp product (Figure 1C).
Note: Primers should be 18–20 bp in length, 40%–60% G-C content, and have similar annealing temperatures.

9. Design forward and reverse primers for PCR 2 that anneal within the product from PCR 1 and will result in a ~200–400 bp product.

Note: The forward primer should be downstream of the forward primer from PCR 1, and the reverse primer should be upstream of the reverse primer from PCR 1 (Figure 1C).

Note: Again, primers should be 18–20 bp in length, 40%–60% G-C content, and have similar annealing temperatures.

### KEY RESOURCES TABLE

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| **Recombinant DNA** |        |            |
| pAAV-FLEX-SaCas9-sgRNA<sup>a</sup> | Addgene | Cat# 124844 |
| pAAV-FLEXfrt-SaCas9-sgRNA<sup>b</sup> | Addgene | Cat# 124845 |
| pAAV-FLEX-EGFP-KASH<sup>a</sup> | Addgene | Cat# 154373 |
| pAAV-FLEXfrt-EGFP-KASH<sup>b</sup> | Addgene | Cat# 154374 |
| **Chemicals, Peptides, and Recombinant Proteins** |        |            |
| D-Sucrose | Fisher | Cat# BP220-212 |
| CaCl<sub>2</sub> | Sigma | Cat# C4901-100G |
| Mg(Ac)<sub>2</sub> | Sigma | Cat# M5661-50G |
| Tris Base | Fisher | Cat# BP152-5 |
| EDTA | Sigma | Cat# ED-500G |
| β-mercaptoethanol | Bio-rad | Cat# 1610710 |
| CutSmart buffer | NEB | Cat# B7204S |
| Ampicillin | Fisher | Cat# BP1760-25 |
| Quick calf intestinal phosphatase (CIP) | NEB | Cat# B5025S |
| Bsal-HF<sub>v2</sub> | NEB | Cat# R3733S |
| HindIII-HF | NEB | Cat# R3104L |
| T<sub>4</sub> polynucleotide kinase (PNK) | NEB | Cat# M0201S |
| T<sub>4</sub> ligase buffer | NEB | Cat# B02025 |
| T<sub>4</sub> ligase | NEB | Cat# M0202S |
| Deoxynucleotide (dNTP) Solution Set | NEB | Cat# N0446S |
| OptiPrep density gradient medium | Sigma | Cat# D1556-250ML |
| Protease Inhibitor Cocktail<sup>i</sup> | Sigma | Cat# P8340 |
| NP-40 Surface-Amps™ Detergent Solution<sup>ii</sup> | Thermo | Cat# 28324 |
| **Experimental Models: Organisms/Strains** |        |            |
| Mouse: Flp or Cre driver lines | n/a | n/a |
| Bacterial and Virus Strains |        |            |
| DH10B electrocompetent E. coli cells | Thermo | Cat# 18290015 |
| Adeno-associated virus serotypes 1-9 | n/a | n/a |
| **Critical Commercial Assays** |        |            |
| QiaQuick gel extraction kit | Qiagen | Cat# 28704 |

(Continued on next page)
Continued

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| MinElute gel extraction kit | Qiagen | Cat# 28604 |
| QiaPrep Spin Miniprep DNA kit | Qiagen | Cat# 27104 |
| Maxiprep DNA kit | Invitrogen | Cat# K21007 |
| REPLI-g Advanced DNA Single Cell kit | Qiagen | Cat# 150363 |
| Phusion High-Fidelity DNA Polymerase kit | Thermo | Cat# F530L |

Software and Algorithms

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| CRISPOR sgRNA prediction algorithm | Concordet and Haeussler, 2018 | crispor.tefor.net |
| ImageJ | Schneider et al., 2012 | https://fiji.sc/ |
| Snapgene software | GSL biotech | Snapgene.com |

Other

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
| MicroPulser Electroporation Apparatus | Bio-Rad | n/a |
| Dounce tissue homogenizers (2 mL) | Millipore Sigma | n/a |
| Precision mouse brain slicer | Braintree Scientific, Inc. | n/a |
| Reusable Biopsy punch | Produstrial | n/a |
| Ultracentrifuge | Thermo or Beckman | n/a |
| BD Aria FACS III | BD Biosciences | n/a |
| Thermocycler | Bio-Rad | n/a |
| High-Performance Conical Tubes (50 mL) | WWR | Cat# 89039-656 |
| High-Performance Conical Tubes (15 mL) | WWR | Cat# 89039-666 |
| Membrane filter, 0.025 um pore size | Millipore | Cat# VSWP01300 |
| Beckman centrifuge tubes 1x31/2 | Beckman | Cat# 344058 |

*Only necessary if gene mutagenesis is Cre-dependent
*Only necessary if gene mutagenesis is Flp-dependent
*Other sources than the ones noted may be used for these products

MATERIALS AND EQUIPMENT

Buffers for Validation of sgRNA Targeting In Vivo

- Homogenization buffer (individual stocks can be stored at 4°C for up to 1 year, but please make fresh Homogenization buffer day of)

| Name | [Stock] | [Final] | Volume to Add |
|------|---------|---------|---------------|
| D-Sucrose | 500 mM | 320 mM | 3.2 mL |
| CaCl2 | 200 mM | 5 mM | 125 μL |
| Mg(Ac)2 | 60 mM | 3 mM | 250 μL |
| Tris (pH=7.8) | 200 mM | 10 mM | 250 μL |
| EDTA (pH=8) | 10 mM | 0.1 mM | 50 μL |
| NP40 | – | 0.1% | 5 μL |
| Protease inhibitor cocktail | 10 mM | 0.1 mM | 50 μL |
| β-mercaptoethanol | 14.2 M | 1 mM | 35.2 μL |
| Water | – | – | 1.035 mL |

Total Volume: 5 mL

- Upper gradient centrifugation buffer (make day of)
STEP-BY-STEP METHOD DETAILS

Insertion of sgRNAs into Vector

**Timing:** 5 days

1. Day 1. Vector Digestion using BsaI
   a. Set up the following reaction using vector of choice (Figures 1D and 1E):

   | Reagents                        | Amount       |
   |--------------------------------|--------------|
   | pAAV-FLEX-SaCas9-sgRNA or pAAV-FLEXfrt-SaCas9-sgRNA | (6–7 μg)     |
   | BsaI-HFv2                       | 1 μL         |
   | ddH2O                           | 4 μL         |
   | Total                           | 40 μL        |

   b. Digest 16 h (overnight) at 37°C.

2. Day 2. Part One – Purification of cut vector
   a. Add 2 μL of Quick CIP and allow reaction to go for 30 min at 37°C.
   b. Run the cut vector on a 1% agarose gel and perform a gel extraction using the Qiagen gel extraction kit following manufacturer instructions.

   **Note:** The linear vector should run at ~7.8 kb.

3. Day 2. Part Two – Anneal and phosphorylate each pair of oligos

   **Note:** Part Two can be completed simultaneously with Part One.

---

**Lower gradient centrifugation buffer (make day of)**

| Name                                | [Stock] | [Final] | Volume to Add |
|-------------------------------------|---------|---------|---------------|
| CaCl₂                               | 200 mM  | 5 mM    | 125 μL        |
| Mg(Ad)₂                             | 60 mM   | 3 mM    | 250 μL        |
| Tris (pH=7.8)                       | 200 mM  | 10 mM   | 250 μL        |
| Protease inhibitor cocktail         | 10 mM   | 0.1 mM  | 50 μL         |
| β-mercaptoethanol                   | 14.2 M  | 1 mM    | 35.2 μL       |
| 60% OptiPrep Gradient               | 60%     | 50%     | 4.17 mL       |
| Water                               | -       | -       | 120 μL        |
| Total volume                        | -       | -       | 5 mL          |

| Name                               | [Stock] | [Final] | Volume to Add |
|------------------------------------|---------|---------|---------------|
| 60% OptiPrep Gradient              | 60%     | 29%     | 4.83 mL       |
| Water                              | -       | -       | 5.17 mL       |
| Total volume                       | -       | -       | 10 mL         |
a. Combine the following reagents:

| Reagent                      | Volume (µL) |
|------------------------------|-------------|
| 100 µM sgRNA primer for      | 1           |
| 100 µM sgRNA primer rev      | 1           |
| ddH2O                        | 6.5         |
| T4 ligase buffer             | 1           |
| T4 polynucleotide kinase (PNK)| 0.5         |
| **Total**                    | **10**      |

b. Incubate for 30 min at 37°C.
c. Boil the reaction at 100°C for 5 min.
d. Turn off the heat and allow the reaction to slowly reach 20°C–22°C (room temperature).

**Alternatives:** This can also be completed using a ramp down protocol in a thermocycler.

4. Day 2. Part Three – Ligate the phosphorylated and annealed oligos into the cut vector
   a. Add 1 µL T4 ligase and ~50 ng of cut vector directly to the reaction from Part Two.
   b. Allow the ligation to sit at 20°C–22°C (room temperature) for 3 h.
   c. Remove excess salts via dialysis.
   d. Transform 1.5 µL of the ligation using 25 µL DH10B electrocompetent *E. coli* cells.
   e. After transformation, quickly resuspend in 500 µL LB.
   f. Allow 1-h recovery in 37°C with shaking and then plate 100 µL on LB + 100 µg/mL AMP antibiotic plates.
   g. Allow the colonies to grow 12–16 h at 37°C.

**Pause Point:** Plate may be stored at 4°C for multiple days.

5. Day 3. Colony selection and miniprep setup
   a. Set up eight minipreps using 3 mL LB + 100 µg/mL AMP in 14 mL tubes that allow aeration.
   b. Place in 37°C with 250 rpm shaking for 12–16 h.

6. Day 4. DNA purification and validation of sgRNA insertion
   a. Perform a miniprep of each of the colonies using the Qiagen miniprep kit to extract the plasmid DNA according to manufacturer instructions.
   b. Prepare the following reaction for each purified colony DNA:

| Reagent            | Volume per Reaction (µL) |
|--------------------|--------------------------|
| DNA [100–300 ng/µL]| 5                        |
| Cutsmart buffer    | 2                        |
| Water              | 12.4                     |
| BsaI-HFv2          | 0.3                      |
| HindIII-HF         | 0.3                      |
| **Total**          | **20**                   |

c. Let each reaction go 3–4 h at 37°C.
d. Run a 1% gel to determine if the oligos inserted.

**Note:** Insertion of the sgRNA into the vector will produce a single band at 7.8 kb. Failure to insert the sgRNA will result in two bands (2.5 kb and 5.3 kb).

e. Select a colony and add 200 µL from miniprep culture in 200 mL LB + 100 µg/mL AMP in a 1L Erlenmeyer flask. Incubate 16 h (overnight) at 37°C with 250 rpm.
7. Day 5. Purification of plasmid DNA
   a. Perform a maxiprep using the Invitrogen maxiprep kit.
   b. Send the DNA to Genewiz for sequencing using the U6 Genewiz Universal primer (sequence: GACTATCATATGCTTACCGT).

   ⚠️ Pause Point: The product can be stored at −20°C for years.

Viral Package, Injection, and Expression

© Timing: >7 weeks

8. Package plasmids into AAVs.

   Note: For packaging DNA into AAVs, please refer to (Gore et al., 2013) for step by step instructions or use a commercial AAV packaging facility.

   △ CRITICAL: AAV serotypes and titer for AAV-FLEX-SaCas9-sgRNA and AAV-FLEX-EGFP-KASH or AAV-FLEXfrt-SaCas9-sgRNA and AAV-FLEXfrt-EGFP-KASH must be the same to maximize co-transduction efficiencies.

9. Co-inject Cre- or Flp-expressing animals with newly synthesized AAV-FLEX-SaCas9-sgRNA or AAV-FLEXfrt-SaCas9-sgRNA (targeting your gene of choice) and AAV-FLEX-EGFP-KASH or AAV-FLEXfrt-EGFP-KASH, respectively (Figure 2A).

   Note: KASH is a protein domain that is inserted into the nuclear envelope. EGFP-KASH integrates EGFP into the nuclear envelope to appropriately identify virally transduced nuclei by EGFP fluorescence (Swiech et al., 2015).

   △ CRITICAL: Viral concentrations should be between 1 and 3 \times 10^{12} particles per mL and injected at a volume of 0.5 mL and rate of 0.25 mL/min. AAV-FLEX-SaCas9-sgRNA and AAV-FLEX-EGFP-KASH should be mixed at equal ratios. Optimal injection volumes, ratios, and viral titers should be tested to ensure optimal expression for each targeted cell type and brain region.

   △ CRITICAL: Allow 4 weeks minimum post-surgery for viral expression, and SaCas9 targeting and genomic DNA cleavage before beginning the next section.

Validation of sgRNA

© Timing: 2 days

10. Day 1. Part One – Homogenize tissue and isolate nuclei

   © Timing: 1–1.5 h

   a. At 4 weeks (or longer) following viral injection, harvest tissues from the injected animals. If harvesting from a localized brain region, slice brain into relatively thin (approx. 500 μm) coronal slices using a precision mouse brain slicer and biopsy punch. 3–6 tissue punches weighing <2 mg each can be combined into a single reaction.
   b. Place 2 mL of cold homogenization buffer in a 2 mL Dounce homogenizer. Keep everything on ice.
   c. Extract the tissue containing the virus injection using a small Biopsy punch.
**Note:** If there is a large amount of tissue, simply divide the tissue into multiple reactions. Too much tissue inhibits efficient homogenization.

**Note:** Tissue from the same region with no viral manipulations is a good negative control for setting gates for FACS. See step 11c for additional instruction.

**Pause Point:** Tissue may be flash frozen in liquid nitrogen and stored at −80°C.

- d. Place the tissue directly into 2 mL of homogenization buffer (**Figure 2B**).
- e. Homogenize the brain slices first by using Dounce A 25x. Then switch to Dounce B 25x.
- f. Pipette this into a 15 mL conical tube on ice.
- g. Add 3 mL of homogenization buffer to bring the volume to 5 mL. Keep on ice for 5 min.
- h. Add 5 mL of Upper gradient centrifugation buffer and mix by inversion.
- i. Gently load on top of 10 mL of the lower gradient centrifugation buffer into 1 × 3.5 Beckman tubes.
- j. Centrifuge at 7,150 × g for 30 min at 4°C.
- k. Remove the suspended debris using a KimWipe and then gently decant the supernatant.
- l. Resuspend in 500–1,000 µL sterile 1× PBS.

11. Day 1. Part Two – FACS using a BD AriaFACS III

**Timing:** 1 h

- a. Place 3 µL of REPLI-g Advanced Single Cell Storage buffer (Qiagen) into each well of an 8-well PCR strip. Keep everything on ice.
- b. Sort using the 70 µm nozzle in single cell mode on a BD AriaFACS III. Sort 500 nuclei per well, which results in 1 µL of sorted cell suspension per well.
- c. Design gates by comparing the negative control (no viral manipulations) to the experimental group. The GFP-positive gate should contain no GFP-negative nuclei as determined by the

---

**Figure 2. Process for the Validation of sgRNAs In Vivo**

(A) Schematic of AAV co-injections into the mouse brain.
(B) Schematic of workflow necessary to prepare nuclei for FACS.
(C) Left: Schematic of proper gating to isolate GFP-negative and GFP-positive nuclei. Right: Example FACS with GFP-negative and GFP-positive gates labeled.
(D) Schematic of workflow for the generation and sequencing of amplicons following FACS. Red arrow: SaCas9 cleavage site.
negative control (Figure 2C). Load the negative control and position the GFP-positive gate such that it contains zero GFP-negative nuclei.

d. Sort both GFP-positive and GFP-negative nuclei.

e. After the sort, keep the samples on ice.

**Pause Point:** Samples may be frozen at –80°C or used directly for whole genome amplification (WGA).

12. Day 1. Part Three – Whole genome amplification

**Timing:** 2.5 h

a. Perform whole genome amplification (WGA) using the REPLI-g Advanced Single Cell kit (Qiagen) according to manufacturer’s instructions (Figure 2D).

**Note:** WGA is used to limit bias during PCR amplification.

b. Dilute 2 μL of WGA FACS DNA into 100 μL of H2O (1:50) and store at 4°C.

**Pause Point:** 1:50 WGA FACS DNA can be stored at 4°C, and the remaining WGA FACS DNA at –20°C for long-term storage.

13. Day 2 (Figure 2D). Amplification of target region

**Timing:** 4 h

a. Set up the following reaction on ice (PCR 1) using the Phusion high-fidelity DNA polymerase kit and first set of PCR primers:

| Reagent                               | Volume (μL) |
|---------------------------------------|-------------|
| 100 μM For primer 1                   | 1           |
| 100 μM Rev primer 1                   | 1           |
| 1:50 diluted WGA FACS DNA             | 1           |
| 10x dNTPs                             | 10          |
| 5x HF buffer                          | 20          |
| Water                                 | 62          |
| DMSO                                  | 3           |
| Phusion                               | 2           |
| **Total Volume**                      | 100 μL      |

b. Mix well, then divide the 100 μL reaction into four 25 μL reactions.

c. Use the following thermocycler protocol:

| Step | Cycle        | Temperature (°C) | Time | Repeat |
|------|--------------|------------------|------|--------|
| 1    | Initial denaturation | 98               | 30 s | x34    |
| 2    | Denaturation  | 98               | 10 s |        |
| 3    | Anneal       | 66               | 20 s |        |
| 4    | Elongation   | 72               | 10 s |        |
| 5    | Final Extension | 72              | 5 min|        |
| 6    | Hold         | 12               | Forever|        |

**Note:** Please refer to potential problems 3–5 in the Troubleshooting section to alter thermocycler protocol accordingly.
d. Combine the four reactions from PCR 1 into a single tube and mix well.
e. Set up the following reaction (PCR 2):

| Reagent                  | Volume (µL) |
|--------------------------|-------------|
| 100 µM For primer 2     | 1           |
| 100 µM Rev primer 2     | 1           |
| PCR 1 reaction          | 1           |
| 10x dNTPs               | 10          |
| 5x HF buffer            | 2           |
| Water                   | 62          |
| DMSO                    | 3           |
| Phusion                 | 2           |
| Total Volume            | 100 µL      |

f. Mix well, then divide the 100 µL reaction into four 25 µL reactions.
g. Use the exact same thermocycler protocol from step 13c.
h. Combine the four reactions from PCR 2 into a single tube and mix well.
i. Run the product on a 2% agarose gel.
j. Gel extract the final product (single band between 200–400 bp) using the MinElute gel extraction kit (Qiagen). Final product may be sent directly to sequencing or may be kept at 20°C for long-term storage.

14. Amplicon-EZ submission
a. Please refer to Genewiz: Amplicon-EZ service for exact submission guidelines.
b. Necessary items:
   i. Reference sequence of amplicon
   ii. PCR 2 forward and reverse primers sequence
   iii. 500 ng (20 ng/µL) of amplicons

EXPECTED OUTCOMES
Genewiz will upload the Amplicon-EZ data onto their server and will provide the login credentials necessary to access this data. The software FileZilla (https://filezilla-project.org/) can be used to access and transfer these files off their server. Once the data is transferred, there will be an Excel file labeled "Plate_abundance" that contains a trimmed sequence and number of reads obtained for every unique amplicon (along with other information). There will be anywhere from 1,000–10,000 unique reads. To remove possible errors due to amplification during PCR, the reads must be trimmed to just contain the sgRNA and PAM sequence. Example data set is below. Reference sequence in A2, sgRNA and PAM bolded, deletion indicated by “–”, insertions are bolded and strike-through. Column A: Unique sequences. Column B: number of reads associated with each unique sequence. A6 contains a mutation that is due to PCR.
Trimming can be achieved by:

1. Copy the amplicon sequences and corresponding read count and move to separate page in Excel.

2. Use the following function in C3 to trim the reads from the left:
   
   \[ \text{=RIGHT(\text{(unique read)}, \text{LEN(unique read)} - \text{(\# of bases)})} \]

   \text{EXAMPLE: } =\text{RIGHT((A3), LEN(A3)-14)}

   \text{RESULT in column C: NNNNNNNNNNNNNNNNNN - - NNGRTNNNNN}

3. Use the following function in D3 to trim the reads from the right:

   \[ \text{=LEFT(\text{(unique read)}, \text{LEN(unique read)} - \text{(\# of bases)})} \]

   \text{EXAMPLE: } =\text{LEFT(C3), LEN(C3)-5)}

   \text{RESULT in column D: NNNNNNNNNNNNNNNNNN - - NNGRR}

This results in only the sgRNA and PAM sequence remaining in column D.

\text{Note: Sequences containing insertions will result in additional bases.}

4. Recalculate the number of reads for each unique sequence using the \text{SUMIF} command. Complete this for all rows:

   \text{EXAMPLE: } =\text{SUMIF(D3:D6,D3,B3:B6)}

   \text{RESULT: 1,004 reads (rows 3 and 6 have the same Cas9-mediated mutation)}

This will result in the number of reads associated with each type of mutation.

\text{LIMITATIONS}

This protocol will confirm mutagenesis by SaCas9 but will not provide the absolute number of edited cells in total. The number of edited reads can vary greatly depending on the positioning of the GFP-positive gate during FACS (Hunker et al., 2020). A more right-shifted gate will result in a higher number of edited reads. This is either due to 1) a higher concentration of virus in the brightest GFP population, resulting in more molecules of SaCas9 and a higher percentage of edited cells or 2) presence of GFP-negative, auto-fluorescing cells in GFP-positive gate.

\text{TROUBLESHOOTING}

\text{Problem 1}

The test digestion used to determine sgRNA insertion resulted in all negative colonies (for steps 6b–6d).

\text{Potential Solution}

There are two possible causes. The first possible cause is the vector digestion did not go to completion (steps 1a–1b). To solve this, digest the vector for a longer amount of time. Run 5 \text{µL} of the reaction on a 1% agarose gel to confirm a single band before moving forward with the gel extraction.

The second possible cause could be that the sgRNA sequence chosen contains a BsaI site. The additional BsaI site would cause the vector to be cut regardless of the insertion of the sgRNA, resulting in false-negative colonies in step 6d. To circumvent this, use PCR to determine sgRNA insertion (see \text{Alternative Protocol 1} below) and skip steps 6b–6d.

\text{Alternative Protocol 1:} PCR can be used to determine sgRNA insertion in place of the digestion. The U6 primer sequence is: GACTATCATGCTTACCGT. The sgRNA primer rev is the reverse primer designed in step 7 of “Before You Begin”. Use the following reaction:
1. Mix well, then add 9 μL to 8 PCR tubes.
2. Add 1 μL of miniprep DNA to each tube.
3. Use the following thermocycler protocol:

| Step | Cycle            | Temperature (°C) | Time   | Repeat |
|------|------------------|------------------|--------|--------|
| 1    | Initial denaturation | 98               | 30 s   |        |
| 2    | Denaturation      | 98               | 10 s   | x34    |
| 3    | Anneal           | 66               | 20 s   |        |
| 4    | Elongation       | 72               | 10 s   |        |
| 5    | Final Extension  | 72               | 5 min  |        |
| 6    | Hold             | 12               | Forever|        |

4. Run on a 2% agarose gel. Positive colonies will have 100 bp product. Negative colonies will have no product.

**Problem 2**
Low numbers (<500 GFP+) of nuclei during FACS (steps 11a–11e).

**Potential Solution**
This was most likely due to insufficient homogenization (steps 10a–10e) caused by too much tissue per sample. To avoid this, after punching the tissue simply split the tissue into multiple reactions (step 10d) and proceed as detailed above. Samples may be recombined following resuspension in step 10i.

**Problem 3**
PCR 2 resulted in multiple bands (steps 13i–13j).

**Potential Solution**
This result could occur for multiple reasons. One, the primers used for PCR amplification could bind to genomic repeat regions. To determine this, display repeat as lowercase letters when obtaining the genomic sequence from the UCSC genome browser. If possible, design the primers upstream or downstream of these regions to avoid them.

If the primers are not in repeat regions, non-specific off-target amplification is occurring. To diminish non-specific amplification, increase the annealing temperature 1°C–2°C.
Problem 4
No bands in PCR 2 (steps 13i–13j).

Potential Solution
The PCR conditions are too stringent. Lower the annealing temperature 1°C–2°C during both PCR 1 (step 13c) and PCR 2 (step 13g) until the proper band is visible.

Problem 5
The band in PCR 2 is the wrong size (steps 13i–13j).

Potential Solution
This is most likely due to a G-C rich region in the amplicon, which can form hairpins during PCR. These hairpins get skipped over by the polymerase, thereby effectively deleting portions of DNA from the amplicon. To avoid this, first determine the location of the G-C rich regions in the genome (>85% G-Cs) and try to design primers to exclude the region (either downstream or upstream of the G-Cs). If the G-C rich region is too close to the sgRNA cut site (<100 bp), design primers that result in a shorter amplicon (~200 bp; steps 8 and 9 in Part Two of “Before You Begin”), increase the annealing temperature (up to 69°C) and use the 5x GC buffer (supplied in the Phusion high-fidelity DNA polymerase kit) in place of the 5x HF buffer during PCR 1 (step 13a) and PCR 2 (step 13e).

RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Larry Zweifel (larryz@uw.edu).

Materials Availability
Plasmids generated in this study have been deposited to Addgene, [124844, 124845, 154373, and 154374].

Data and Code Availability
This study did not generate any unique datasets or code.

ACKNOWLEDGMENTS
This work was supported by NIH grants P30-DA048736, R01-MH104450, and R01-DA044315 (L.S.Z.) and F31-MH116549 and T32GM007270 (A.C.H.); the Brain and Behavior Research Foundation NARSAD Independent Investigator Award (L.S.Z.); and the University of Washington Innovator Award (L.S.Z.). We thank Donna Prunkard and Xiaoping Wu for assistance with FACS, and members of the Zweifel lab for thoughtful discussion.

AUTHOR CONTRIBUTIONS
A.C.H. and L.S.Z. conceptualized the study, designed experiments, analyzed data, and wrote the paper. A.C.H. performed all plasmid and AAV synthesis, FACS, and sequencing analysis.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
Bult, C.J., Blake, J.A., Smith, C.L., Kadin, J.A., and Richardson, J.E. (2019). Mouse Genome Database (MGD) 2019. Nucleic Acids Res. 47, D801–D806.

Concordet, J.P., and Haeussler, M. (2018). CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens. Nucleic Acids Res. 46, W242–W245.

Gore, B.B., Soden, M.E., and Zweifel, L.S. (2013). Manipulating gene expression in projection-specific neuronal populations using combinatorial viral approaches. Curr. Protoc. Neurosci. 65, 4.35.1–4.35.20.

Haeussler, M., Schonig, K., Eckert, H., Eschstruth, A., Mianne, J., Renaud, J.B., Schneider-Maunoury, S., Shkumatava, A., Teboul, L., Kent, J., et al. (2016). Evaluation of off-target and on-target scoring
algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 17, 148.

Hunker, A.C., Soden, M.E., Krayushkina, D., Heymann, G., Awatramani, R., and Zweifel, L.S. (2020). Conditional single vector CRISPR/SaCas9 viruses for efficient mutagenesis in the adult mouse nervous system. Cell Rep. 30, 4303–4316.e6.

Ran, F.A., Cong, L., Yan, W.X., Scott, D.A., Gootenber, J.S., Kriz, A.J., Zetsche, B., Shalem, O., Wu, X., Makarova, K.S., et al. (2015). In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191.

Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675.

Smith, C.M., Hayamizu, T.F., Finger, J.H., Bello, S.M., McCright, I.J., Xu, J., Baldarelli, R.M., Beal, J.S., Campbell, J., Corbani, L.E., et al. (2019). The mouse Gene Expression Database (GXD). 2019 update. Nucleic Acids Res. 47, D774–D779.

Swiech, L., Heidenreich, M., Banerjee, A., Habib, N., Li, Y., Trombetta, J., Sur, M., and Zhang, F. (2015). In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9. Nature Biotechnol. 33, 102–106.

Waterston, R.H., Lindblad-Toh, K., Birney, E., Rogers, J., Abril, J.F., Agarwal, P., Agarwala, R., Ainscough, R., Alexandersson, M., An, P., et al. (2002). Initial sequencing and comparative analysis of the mouse genome. Nature 420, 520–562.